Inventor · disambiguated record
Hans Loibner
Also filed as: LOIBNER HANS
32 granted patents·29 pending applications·195 citations·filing 1982–2023
96Inventor score
Files withAPEIRON BIOLOGICS AG15IGENEON KREBS IMMUNTHERAPIE9LOIBNER HANS9ATTOQUANT DIAGNOSTICS GMBH3SANDOZ LTD3
Top patents by PatentIndex Score
61 records- 0190US10294305B2Method for treating a GD2 positive cancerAPEIRON BIOLOGICS AG·Filed 2014·Granted May 21, 2019·20 cites·21 claims
- 0289US9840566B2Preparations and methods for treating a GD2 positive cancerAPEIRON BIOLOGICS AG·Filed 2014·Granted Dec 12, 2017·7 cites·16 claims
- 0389US9777068B2Method for treating a GD2 positive cancerLOIBNER HANS·Filed 2012·Granted Oct 3, 2017·17 cites·19 claims
- 0489US8241864B2Method for determining ACE2 activityLOIBNER HANS·Filed 2007·Granted Aug 14, 2012·10 cites·26 claims
- 0587US9561263B2Treatment of inflammatory illnesses with ACE2LOIBNER HANS·Filed 2008·Granted Feb 7, 2017·11 cites·3 claims
- 0686US5562903AHumanized antibodies that recognize difucosyl Lewis blood group antigens Y-6 and B-7-2SANDOZ LTD·Filed 1993·Granted Oct 8, 1996·69 cites·12 claims
- 0784US8586319B2Recombinant ACE2 polypeptide dimerSCHUSTER MANFRED·Filed 2008·Granted Nov 19, 2013·10 cites·12 claims
- 0881US8809288B2Method for increasing immunoreactivityBAIER GOTTFRIED·Filed 2008·Granted Aug 19, 2014·15 cites·20 claims
- 0979US7527789B2Use of a preparation based on an antibody directed against a tumor-associated glycosylationIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Granted May 5, 2009·9 cites·28 claims
- 1075US2023340148A1Method for treating a gd2 positive cancerAPEIRON BIOLOGICS AG·Filed 2022·Application pending·0 cites
- 1174US2024158530A1Preparations and methods for treating a gd2 positive cancerAPEIRON BIOLOGICS AG·Filed 2023·Application pending·0 cites
- 1272US6956119B2Polysaccharide-polypeptide conjugateLOIBNER HANS·Filed 2001·Granted Oct 18, 2005·4 cites·19 claims
- 1369US11492412B2Preparations and methods for treating a GD2 positive cancerAPEIRON BIOLOGICS AG·Filed 2021·Granted Nov 8, 2022·0 cites·26 claims
- 1469US10995147B2Preparations and methods for treating a GD2 positive cancerAPEIRON BIOLOGICS AG·Filed 2020·Granted May 4, 2021·0 cites·1 claims
- 1568US9186373B2SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancerLAMETSCHWANDTNER GÜNTHER·Filed 2011·Granted Nov 17, 2015·4 cites·8 claims
- 1668US8946162B2Treatment of tumorsJANZEK-HAWLAT EVELYNE·Filed 2009·Granted Feb 3, 2015·2 cites·9 claims
- 1767US9839668B2Compositions and methods for the treatment of diseases related to the renin-angiotensin-systemATTOQUANT DIAGNOSTICS GMBH·Filed 2014·Granted Dec 12, 2017·1 cites·23 claims
- 1865US11597775B2Preparations and methods for treating a GD2 positive cancerAPEIRON BIOLOGICS AG·Filed 2017·Granted Mar 7, 2023·0 cites·14 claims
- 1965US11447565B2Method for treating a GD2 positive cancerAPEIRON BIOLOGICS AG·Filed 2017·Granted Sep 20, 2022·0 cites·22 claims
- 2064US8034338B2Immunogenic recombinant antibodyIGENEON KREBS IMMUNTHERAPIE·Filed 2004·Granted Oct 11, 2011·4 cites·6 claims
- 2164US4503046A1-Nitro-aminoglycoside derivatives, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticalsSANDOZ LTD·Filed 1982·Granted Mar 5, 1985·10 cites·10 claims
- 2264US2009130125A1Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancerIGENEONG KREBS IMMUNTHERAPIE F·Filed 2008·Application pending·0 cites
- 2361US8153135B2Polysaccharide-polypeptide conjugateLOIBNER HANS·Filed 2005·Granted Apr 10, 2012·0 cites·13 claims
- 2461US2005255116A1Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancerIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Application pending·0 cites
- 2560US7759464B2N-glycosylated antibodyGREENOVATION BIOTECH GMBH·Filed 2004·Granted Jul 20, 2010·0 cites·12 claims
- 2659US2020055953A1Method for Treating a GD2 Positive CancerAPEIRON BIOLOGICS AG·Filed 2019·Application pending·0 cites
- 2758US11079398B2Method for measurement of peptidic degradation products of a proteolytic cascade in blood samplesATTOQUANT DIAGNOSTICS GMBH·Filed 2017·Granted Aug 3, 2021·0 cites·27 claims
- 2858US10716833B2Method for producing ACE2 polypeptideAPEIRON BIOLOGICS AG·Filed 2017·Granted Jul 21, 2020·0 cites·6 claims
- 2957US7691372B2Use of antibodies for the vaccination against cancerIGENEON KREBS IMMUNTHERAPIE·Filed 2006·Granted Apr 6, 2010·0 cites·19 claims
- 3056US2010233178A1Use of antibodies for the vaccination against cancerECKERT HELMUT·Filed 2009·Application pending·0 cites
- 3154US2009181030A1Use of a preparation based on an antibody directed against a tumor-associated glycosylationIGENEON KREBS IMMUNTHERAPIE·Filed 2009·Application pending·0 cites
- 3254US2023213517A1Method for detecting virus particles and kits thereforCOVIRABIO GMBH·Filed 2021·Application pending·0 cites
- 3354US2016000914A1Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancerGREENOVATION BIOTECH GMBH·Filed 2015·Application pending·0 cites
- 3453US2014099297A1Ace2 polypeptideAPEIRON BIOLOGICS AG·Filed 2013·Application pending·0 cites
- 3553US2004265318A1Use of antibodies for the vaccination against cancerIGENEON KREBS IMMUNOTHERAPIE F·Filed 2004·Application pending·0 cites
- 3652US2005169929A1Use of a vaccine for active immunization against cancerFiled 2003·Application pending·0 cites
- 3752US2005181475A1Immunogenic monoclonal antibodyIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Application pending·0 cites
- 3851US2006018901A1Use of antibodies in a very low dose for the vaccination against cancerLOIBNER HANS·Filed 2005·Application pending·0 cites
- 3951US2006246056A1Immunotherapy of rectal cancerIGENEON KREBS IMMUNTHERAPIE·Filed 2004·Application pending·0 cites
- 4051US2010316624A1Treatment of fibroses and liver disordersLOIBNER HANS·Filed 2008·Application pending·0 cites
- 4150US2006127403A1Use of antibodies against tumor-associated antigenIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Application pending·0 cites
- 4249US8062625B2Cancer immunotherapy predictive parametersLOIBNER HANS·Filed 2007·Granted Nov 22, 2011·0 cites·14 claims
- 4348US9684004B2Method for measurement of peptidic degradation products of a proteolytic cascade in blood samplesPOGLITSCH MARKO·Filed 2012·Granted Jun 20, 2017·0 cites·19 claims
- 4448US2004151717A1Use of polyclonal immunoglobulinsFiled 2002·Application pending·0 cites
- 4548US2010028932A1General prognostic parameters for tumour patientsWOLFGANG STOIBER·Filed 2007·Application pending·0 cites
- 4647US8444974B2Use of antibodies for the vaccination against cancerECKERT HELMUT·Filed 2011·Granted May 21, 2013·0 cites·8 claims
- 4747US8323650B2Method of treating lewis Y-expressing tumorsSCHUSTER MANFRED·Filed 2010·Granted Dec 4, 2012·0 cites·20 claims
- 4847US2018117126A1Treatment of inflammatory illnesses with ace2APEIRON BIOLOGICS AG·Filed 2017·Application pending·0 cites
- 4946US2010310551A1Immunogenic, monoclonal antibodyMERIDIAN BIOPHARMACEUTICALS GMBH·Filed 2010·Application pending·0 cites
- 5045US9757433B2Modified ACE2 polypeptidesApeiron Biologicals AG·Filed 2014·Granted Sep 12, 2017·0 cites·11 claims
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hans Loibner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →